Skip to main
NRSN
NRSN logo

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics Ltd is positioned favorably due to its positive clinical trial results, with the Phase 2b PARADIGM study achieving a statistically significant 29.2% slowing in disease progression for patients treated with its product candidate, PrimeC. The therapy demonstrated not only effectiveness but also favorable safety and tolerability, alongside biomarker-driven evidence of target engagement, reinforcing its potential as a viable treatment option. Additionally, the convergence of regulatory and clinical milestones is anticipated to spur opportunities for strategic partnerships in North America and Europe, further enhancing the company's growth prospects.

Bears say

NeuroSense Therapeutics Ltd is facing a concerning financial situation as its cash reserves are diminishing, indicating a potential liquidity crisis. The expectation of an impending capital raise suggests that the company may struggle to fund ongoing operations and clinical trials without additional financial support. This situation raises flags regarding the company's ability to execute its development plans for its key product candidate, PrimeC, which could adversely affect investor confidence and stock performance.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.